Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.

Guardado en:
Detalles Bibliográficos
Autores principales: Yi Ding, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin H. Lin, Gehao Liang, Lifeng Yuan, Handan Xiang, Junying Chen, Tao Yin, Peter B. Alexander, Qian-Fei Wang, Er-Wei Song, Qi-Jing Li, Kris C. Wood, Xiao-Fan Wang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/3b4653d4e9534695875c3adfe802cb21
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/3b4653d4e9534695875c3adfe802cb21

Ejemplares similares